These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 2203517)
61. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Fizazi K; Scher HI; Molina A; Logothetis CJ; Chi KN; Jones RJ; Staffurth JN; North S; Vogelzang NJ; Saad F; Mainwaring P; Harland S; Goodman OB; Sternberg CN; Li JH; Kheoh T; Haqq CM; de Bono JS; Lancet Oncol; 2012 Oct; 13(10):983-92. PubMed ID: 22995653 [TBL] [Abstract][Full Text] [Related]
62. Relapse on endocrine treatment in patients with stage D2 prostate cancer. Does second-line hormonal therapy affect survival? Matzkin H; Rangel MC; Soloway MS Urology; 1993 Feb; 41(2):144-8. PubMed ID: 8497986 [TBL] [Abstract][Full Text] [Related]
63. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M; Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877 [TBL] [Abstract][Full Text] [Related]
64. Pharmacological and clinical studies of the antiandrogen Anandron. Moguilewsky M; Bertagna C; Hucher M J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565 [TBL] [Abstract][Full Text] [Related]
65. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893 [TBL] [Abstract][Full Text] [Related]
66. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
67. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K; Lehnert M; Stettner H; Hubmer G Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791 [TBL] [Abstract][Full Text] [Related]
68. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2. Jørgensen T; Tveter KJ; Jørgensen LH Eur Urol; 1993; 24(4):466-70. PubMed ID: 8287887 [TBL] [Abstract][Full Text] [Related]
69. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers]. Jonville AP; Diot E; Dutertre JP; Autret E Therapie; 1992; 47(5):393-7. PubMed ID: 1299978 [TBL] [Abstract][Full Text] [Related]
70. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy]. Ohlmann CH Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763 [TBL] [Abstract][Full Text] [Related]
71. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201 [TBL] [Abstract][Full Text] [Related]
73. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766 [TBL] [Abstract][Full Text] [Related]
74. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer. Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407 [TBL] [Abstract][Full Text] [Related]
75. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study. Navratil H Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551 [No Abstract] [Full Text] [Related]
77. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Schellhammer PF Urology; 1996 May; 47(5):622-8. PubMed ID: 8650856 [No Abstract] [Full Text] [Related]
78. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK; J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084 [TBL] [Abstract][Full Text] [Related]
79. Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. Ask K; Dijols S; Giroud C; Casse L; Frapart YM; Sari MA; Kim KS; Stuehr DJ; Mansuy D; Camus P; Boucher JL Chem Res Toxicol; 2003 Dec; 16(12):1547-54. PubMed ID: 14680368 [TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetics and metabolism of nilutamide. Creaven PJ; Pendyala L; Tremblay D Urology; 1991; 37(2 Suppl):13-9. PubMed ID: 1992598 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]